SACITUZUMAB - GOVITECAN ( TRODELVI BY GILEAD ) AS SECOND-LINE TREATMENT IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CÁNCER . QUE DECIR DE UNA PFS DE 4,4 MESES Y UNA OS DE 13,6 MESES .
KEY TAKEAWAYS :
SACITUZUMAB GOVITECAN MAY BE AN EFFECTIVE SECOND-LINE THERAPY IN SMALL CELL LUNG CÁNCER .
The MEDIAN PFS Was 4.40 Months ( 95% CI, 3.81-6.11 ), And The 8-Month PFS Rate Was 36.6% .
The MEDIAN OS Was 13.60 Months ( 95% CI, 6.57-14.78 ), And The 12-Month OS Rate Was 50.3% .
A Total of 76.7% Of Patients Experienced Tumor Shrinkage, And 48.8% Of Patients Had a Target Lesion Diameter Reduction Of Greater Than 30% . ...